fda glp-1 compounding warning october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA issued 25 warning letters

supplementation has demonstrated increased maximal oxygen consumption and modest weight loss in meta-analyses of overweight adults

Additionally, the pQCT data hinted that the observed increase in cortical BMC might have originated from an increase in the cross-sectional area of the bone

Additional research has demonstrated that correcting vitamin D deficiency can, in itself, increase glutathione levels and vice versa

l-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors

How to decide which medication is right for you The choice between Qsymia and a GLP-1 medication is not one you should make alone